Drug Trial Radar · NCT07690189
Study of NTB-928 in R/R OC
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Jun 29, 2026
Primary completion
Jun 2028
Study completion Feb 2029
Sponsor
- Lead sponsor
- TeneoSeven, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to determine if NTB-928 can be given safely to adult females with ovarian cancer that has come back (relapsed) or stopped responding to treatment (refractory), how NTB-928 moves through the body, and how the immune system reacts to it. The study will also look for early signs of anti-cancer activity of NTB-928. The main questions the study aims to answer are: * What side effects do participants experience when receiving NTB-928, including side effects that limit how much of it can be safely given? * How is NTB-928 processed by the body at different dose levels? * Does the immune system react to NTB-928 during treatment? * What dose of NTB-928 can be given safely that shows early signs of activity against ovarian cancer?
Conditions
- Relapsed/Refractory Ovarian Carcinoma
Interventions
NTB-928Drug
NTB-928 is an investigational study drug administered as an intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of dose-limiting toxicities (DLTs) within the first cycle of treatment with NTB-928Time frame: Up to 35 days
- Number of participants with adverse events (AEs) and serious adverse events (SAEs), by severity and relatedness to NTB-928Time frame: Up to approximately 3 years
- Maximum plasma concentration (Cmax)Time frame: Up to approximately 3 years
- Time to Cmax (Tmax)Time frame: Up to approximately 3 years
- Area under the plasma concentration-time curve (AUC) over the dosing interval (AUC0-T)Time frame: Up to approximately 3 years
- AUC from time zero to time t (AUC0-t)Time frame: Up to approximately 3 years
- AUC from time 0 extrapolated to infinity (AUC0-∞)Time frame: Up to approximately 3 years
- Terminal elimination half-life (t½)Time frame: Up to approximately 3 years
- Clearance (CL)Time frame: Up to approximately 3 years
- Terminal elimination rate constant (λz)Time frame: Up to approximately 3 years
- Volume of distribution (Vz)Time frame: Up to approximately 3 years
- Accumulation ratio (Rac) for Cmax and AUC, and trough concentration (Ctrough)Time frame: Up to approximately 3 years
- Number of participants with anti-drug antibodies (ADA) at baseline and after treatmentTime frame: Up to approximately 3 years
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
The University of Alabama
Birmingham, Alabama · Recruiting
University of California San Francisco Health - Hereditary Cancer Clinic - Mission Bay
San Francisco, California · Recruiting
University of Colorado Anschutz Cancer Center - Anschutz Cancer Pavilion
Aurora, Colorado · Recruiting
University of Nebraska Medical Center
Omaha, Nebraska · Recruiting
START Northwell, LLC
Lake Success, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.